PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Feb 20, 2018
SOUTH PLAINFIELD, N.J., Feb. 20, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's prior position and denied PTC's appeal of the Complete Response Letter in relation to the New Drug Application (NDA) for ataluren. In its letter, t...
Feb 13, 2018
SOUTH PLAINFIELD, N.J., Feb. 13, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is delighted to announce the launch of the fourth annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne Muscular Dystrophy (DMD). The STRIVE Awards provide funds to patient advocacy organizations to develop...
Feb 9, 2018
SOUTH PLAINFIELD, N.J., Feb. 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22nd at 2:35 pm ET. The presentation will be webcast live on the Events and Presentations page...
Jan 27, 2018
SOUTH PLAINFIELD, N.J., Jan. 27, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of early interim data from Part 1, the dose-finding portion of the FIREFISH study. FIREFISH is a two-part seamless, open-label, multi-center study to investigate the safety and efficacy of RG7916 in infants and babies with Ty...
Jan 23, 2018
SOUTH PLAINFIELD, N.J., Jan. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that updates and preliminary data from ongoing clinical trials of RG7916, an oral survival motor neuron 2 (SMN2) splicing modifier in SMA patients will be presented at the International Scientific Congress on Spinal Muscular Atrophy at Jagiel...
Jan 8, 2018
SOUTH PLAINFIELD, N.J., Jan. 8, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a corporate update, which will be detailed as part of the company's presentation at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th at 2:30 pm PT. Stuart W. Peltz, Ph.D., PTC's Chief Executive Officer, will highligh...
Jan 5, 2018
SOUTH PLAINFIELD, N.J., Jan. 5, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 3, 2018 it approved non-statutory stock options to purchase an aggregate of 33,200 shares of its common stock to seven new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the ...
Jan 3, 2018
SOUTH PLAINFIELD, N.J., Jan. 3, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 36th Annual JP Morgan Healthcare Conference on Wednesday, January 10th at 2:30 pm PT. The presentation will be webcast live on the Events and Presentations page under the...
Dec 15, 2017
SOUTH PLAINFIELD, N.J., Dec. 15, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 11, 2017 it approved non-statutory stock options to purchase an aggregate of 10,000 shares of its common stock to two new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the...
Nov 20, 2017
SOUTH PLAINFIELD, N.J., Nov. 20, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 15, 2017 it approved non-statutory stock options to purchase an aggregate of 61,500 shares of its common stock to eight new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of t...
Page:
1
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue